#1 Clinical Trials Search in Europe

SONLICROMANOL HYDROCHLORIDE

Clinical trials are investigating SONLICROMANOL HYDROCHLORIDE in people with long COVID. These studies are looking at whether it can improve fatigue and how well it works compared with placebo, which is an inactive look-alike treatment. The main target population is adults with post-COVID symptoms, especially fatigue.

Table of Contents

Trial overview

The listed study of SONLICROMANOL HYDROCHLORIDE is a randomized, double-blind, placebo-controlled Phase 2 trial in people with long COVID.[1] It is an interventional study, which means the researchers assign a treatment and then measure the results.[1]

The trial is authorised and plans to enroll 80 participants.[1] Its brief summary says the study is looking at reduction of post-COVID related fatigue measured with the FAS at week 13.[1]

Who is being studied

The target condition is long COVID, also called post-COVID symptoms in the study summary.[1] The main symptom being studied is fatigue, which means ongoing tiredness or low energy.[1]

This means the trial is focused on people whose symptoms continue after a COVID-19 infection, especially those affected by persistent fatigue.[1]

Study design and treatment groups

The trial is randomized, so participants are assigned to study groups by chance.[1] It is also double-blind, which means neither the participants nor the study team know who receives the active treatment or the placebo during the study.[1]

The comparison is between SONLICROMANOL HYDROCHLORIDE and placebo, an inactive look-alike treatment used to help show whether the study drug has a real effect.[1] The intervention list includes Sonlicromanol tablets and a placebo, and also lists Sonlicromanol 180 mg by buccal use.[1]

What is being measured

The primary outcome is fatigue symptoms measured at week 13 by the FAS.[1] A primary outcome is the main result the researchers want to study.[1]

The FAS is a fatigue assessment scale, which is a tool used to measure how severe tiredness is.[1] In simple terms, the study wants to see whether SONLICROMANOL HYDROCHLORIDE can improve fatigue more than placebo after 13 weeks.[1]

Trial status and size

The study status is Authorised, which means it has approval to proceed.[1] With 80 planned participants, this is a small Phase 2 study designed to give an early answer about possible benefit in long COVID fatigue.[1]

Because the trial is still in Phase 2, the main goal is to learn more about whether the treatment may help and to continue evaluating it in a limited group of patients.[1]

Trial ID Phase Condition studied Status Enrollment
2025-521866-92-01 Phase 2 Long COVID Authorised 80

FAQ

  • What are the clinical trials of SONLICROMANOL HYDROCHLORIDE studying? The trial is studying whether SONLICROMANOL HYDROCHLORIDE can reduce fatigue in people with long COVID. It compares the study drug with placebo to see if there is a real benefit.
  • Who may take part in these trials? The target group is people with long COVID. The trial is focused on patients who still have fatigue after COVID-19.
  • What phase is the SONLICROMANOL HYDROCHLORIDE trial? The study is a Phase 2 trial. Phase 2 trials usually look more closely at whether a treatment works and continue to check safety.
  • How many people are planned for the study? The trial plans to include 80 participants. This is a relatively small study, which is common in early testing phases.
  • What outcome is being measured? The main outcome is fatigue symptoms at week 13, measured by the FAS. The FAS is a fatigue assessment scale, which is a tool used to rate how severe tiredness is.

Ongoing Clinical Trials on SONLICROMANOL HYDROCHLORIDE

  • A Study of Sonlicromanol for Reducing Fatigue in Patients with Long COVID

    Recruiting

    2 1
    Investigated drugs:
    The Netherlands

Glossary

  • Long COVID: Health problems that continue after a COVID-19 infection. In this trial, the main problem being studied is fatigue.
  • Fatigue: Strong tiredness or low energy that does not improve well with rest.
  • Placebo: An inactive look-alike treatment used for comparison. It helps researchers see whether the study drug works better than no active treatment.
  • Randomized: People are assigned to treatment groups by chance. This helps make the comparison fair.
  • Double-blind: Neither the participants nor the study team know who gets the study drug or placebo during the trial. This helps reduce bias.
  • Phase 2: A trial stage that checks whether a treatment may work and continues to watch safety in a small group of people.
  • Interventional study: A study where researchers give a treatment and then measure the results.
  • Enrollment: The planned number of people who will join the study.
  • Primary outcome: The main result the researchers want to measure.
  • FAS: A fatigue scale used to measure how bad tiredness is. Higher or lower scores can show changes over time.

References

  1. https://clinicaltrials.gov/study/2025-521866-92-01